On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – Results from the EUROCARE-5 study
Introduction
Colorectal cancer (CRC) is among the commonest cancers in Europe, accounting for an estimated 471,000 new cases and 228,000 deaths in 2012 [1].
Previous studies using population-based cancer registry (CR) data revealed major variation in survival for patients with colon and rectum cancer in Europe [2], [3]. Major findings included (i) age-related differences in the survival for CRC patients with lower survival for elderly ones, and (ii) geographical variation with lower survival particularly observed for patients from Eastern Europe. Mortality rates decreased throughout most European countries and this was accompanied by a sustained increase in population-based survival for CRC patients in many countries, whilst incidence rates increased modestly in men and remained stable in women, respectively [4].
Possible reasons for the higher incidence rates observed in Europe as well as in many developed regions [1] are life style related factors with increased consumption of sugar, red and processed meat, less consumption of fibre and physical activity, which result in an increased amount of overweight people [5]. The aforementioned increase in survival, especially in younger patients, has been attributed to advances in detection and treatment of CRC during the past 20 years including increased availability of colonoscopy, improved surgery and more widespread use of radiotherapy for rectal cancers [3].
This EUROCARE-5 paper aims to update available knowledge from previous population-based survival studies and to provide the latest survival estimates for patients with invasive malignant colon and rectum cancers from Europe.
Section snippets
Study database
The study analysed data of patients followed up to the end of 2008 and diagnosed with invasive malignant cancer of the colon and rectum, anal canal and anus (ICD-O-3 topography codes: C18-C21, morphology codes: 8000/3-9589/3, according to International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) [6]). We analysed a first dataset including 1,054,018 patients diagnosed with CRC in 2000–2007 from 29 European countries provided by 89 population-based CRs and grouped into five
Results
Table 1 provides an overview on the included patients. Altogether, 1,054,018 CRC patients representing 96% of all registered cancers were included into the survival analyses. The proportions of DCO notified cases and cancer cases without microscopic verification were less than 5% and less than 10%, respectively, in each European region. Overall, 51% of the patients were aged 55–74 years at diagnosis. The proportion of elderly patients aged 75+ years was highest in Northern Europe and Ireland and
Discussion
This article presents patterns and trends in survival for patients diagnosed with CRC from different European countries and regions. European average 5-year RS of patients who were diagnosed with colon and rectum cancers in 2000–2007 was 57% and 56%, respectively. The analyses demonstrated persistent differences in the survival of patients with colon and rectum cancer across Europe with below average survival consistently observed in Eastern Europe. Similar increases in patient survival were
Conclusions
To summarise, this study updates previous studies and reveals on-going improvement of survival for patients with CRC in Europe between 1999 and 2007. It highlighted the persistent differences in survival for patients with CRC within Europe, with lowest survival observed for patients from Eastern Europe. Several screening strategies have meanwhile been demonstrated to have a large potential to reduce mortality from colon and rectum cancer, and their implementation might carry a large potential
Role of the funding source
The study was funded by the Compagnia di San Paolo, the Fondazione Cariplo Italy, the Italian Ministry of Health (Ricerca Finalizzata 2009, RF-2009-1529710) and the European Commission (European Action Against Cancer, EPAAC, Joint Action No. 20102202). The funding sources had no role in study design, the collection, analysis or interpretation of data, the writing of the report, or the decision to submit the article for publication.
Conflict of interest statement
None declared.
Acknowledgements
We thank Chiara Margutti, Simone Bonfarnuzzo and Camilla Amati for secretarial assistance.
References (46)
- et al.
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
Eur J Cancer
(2009) - et al.
Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s
Eur J Cancer
(2008) - et al.
The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis
Eur J Cancer
(2009) - et al.
Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications
Eur J Cancer
(2004) An empirical evaluation of period survival analysis using data from the Canadian Cancer Registry
Ann Epidemiol
(2006)- et al.
Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data
Eur J Cancer
(2004) - et al.
Standard cancer patient population for age standardising survival ratios
Eur J Cancer
(2004) - et al.
Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory
Eur J Cancer
(2015) - et al.
Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980
Ann Oncol
(2013) - et al.
Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)
Lancet
(2015)
Colorectal cancer prevention in Europe: burden of disease and status of screening programs
Prev Med
Prevention, early detection, and overdiagnosis of colorectal cancer within 10 years of screening colonoscopy in Germany
Clin Gastroenterol Hepatol
Surgical issues in rectal cancer: a 2004 update
Clin Colorectal Cancer
Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity
Acta Oncol
European health systems and cancer care
Ann Oncol
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
Lancet
Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study
Lancet Oncol
Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005
Clin Oncol (R Coll Radiol)
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11
Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study
Int J Cancer
Cited by (97)
Colorectal cancer recurrence and its impact on survival after curative surgery: An analysis based on multistate models
2023, Digestive and Liver DiseaseSurvival trends in patients diagnosed with colon and rectal cancer in the nordic countries 1990–2016: The NORDCAN survival studies
2022, European Journal of CancerCitation Excerpt :While colon and rectal cancer survival improved in all Nordic countries, the most marked change was observed in Denmark. The result from several earlier studies has shown poorer survival in patients with colon and rectal cancer in Denmark [3,16], findings which at least partly have been attributed to differences in the proportion of patients receiving curative surgery [19]. Changes in Denmark that may explain recent improvements include the launch of national cancer plans in 2000 with earmarked funding for cancer care, introduction of accelerated cancer patient pathways in 2007, improved access to endoscopic investigations, centralization of cancer surgery, and improvements in postoperative care [20,21].
Assessment of prognostic factors in long-term survival of male and female patients with colorectal cancer using non-mixture cure model based on the Weibull distribution
2021, Surgical OncologyCitation Excerpt :In the United States (US), this rate was about 65% in which females had higher probability to be cured than males [29]. According to the information extracted from 29 population-based studies on cancer registries carried out in the Europe, 5-year survival rate of CRC patients was about 63% in this continent [30]. Moreover, recently, some countries in East-Asia such as South Koran and Japan, reported a rapid increase for the 5-year survival rate of CRC.
Evaluation of a risk score based on dietary and lifestyle factors to target a population at risk in colorectal cancer screening
2021, Digestive and Liver DiseasePlace of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020
2020, Journal of Geriatric Oncology